Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences.
作者信息
Kim In-Ho, Choi Wonyoung, Han Hye Sook
机构信息
Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Center for Clinical Trials, National Cancer Center, Goyang, Korea.
出版信息
J Gastric Cancer. 2024 Oct;24(4):353-355. doi: 10.5230/jgc.2024.24.e40.
Abstract
摘要
相似文献
1
Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences.
J Gastric Cancer. 2024 Oct;24(4):353-355. doi: 10.5230/jgc.2024.24.e40.
2
The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences.
J Gastric Cancer. 2024 Jul;24(3):243-245. doi: 10.5230/jgc.2024.24.e26.
3
Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.
Cancer Res Treat. 2020 Oct;52(4):1178-1187. doi: 10.4143/crt.2020.313. Epub 2020 Jun 11.
4
The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses.
Int J Cancer. 2015 Aug 15;137(4):819-25. doi: 10.1002/ijc.29449. Epub 2015 Feb 26.
5
Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial.
Yonsei Med J. 2019 Feb;60(2):132-139. doi: 10.3349/ymj.2019.60.2.132.
6
A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer.
Cancer Res Treat. 2020 Oct;52(4):1153-1161. doi: 10.4143/crt.2020.173. Epub 2020 May 4.
7
Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study.
Ann Surg Oncol. 2021 Dec;28(13):8908-8915. doi: 10.1245/s10434-021-10084-0. Epub 2021 Aug 16.
8
Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection.
Int J Cancer. 2012 Jul 15;131(2):505-11. doi: 10.1002/ijc.26399. Epub 2011 Nov 19.
9
Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.
Ann Surg Oncol. 2022 Apr;29(4):2324-2331. doi: 10.1245/s10434-021-11050-6. Epub 2021 Nov 18.
10
Survival impact of microsatellite instability in stage II gastric cancer patients who received S-1 adjuvant monotherapy after curative resection.
Sci Rep. 2023 Jul 4;13(1):10826. doi: 10.1038/s41598-023-37870-y.
引用本文的文献
1
The Current Evidence and Future Direction of Adjuvant Treatment for Gastric Cancer in the Era of Precision Medicine.
Cancer Res Treat. 2025 Jul;57(3):621-634. doi: 10.4143/crt.2024.1222. Epub 2025 Jan 23.
本文引用的文献
1
The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences.
J Gastric Cancer. 2024 Jul;24(3):243-245. doi: 10.5230/jgc.2024.24.e26.
2
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Lancet Gastroenterol Hepatol. 2024 Aug;9(8):705-717. doi: 10.1016/S2468-1253(24)00156-0. Epub 2024 Jun 18.
3
Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis.
Ther Adv Med Oncol. 2024 Feb 29;16:17588359241231259. doi: 10.1177/17588359241231259. eCollection 2024.
4
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.
Cancer Commun (Lond). 2024 Jan;44(1):127-172. doi: 10.1002/cac2.12516. Epub 2023 Dec 31.
5
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Lancet Oncol. 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7. Epub 2023 Dec 19.
6
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
J Clin Oncol. 2024 Feb 1;42(4):410-420. doi: 10.1200/JCO.23.00975. Epub 2023 Nov 14.
7
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach.
J Gastric Cancer. 2023 Jan;23(1):3-106. doi: 10.5230/jgc.2023.23.e11.
8
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
J Clin Oncol. 2023 Jan 10;41(2):255-265. doi: 10.1200/JCO.22.00686. Epub 2022 Aug 15.
9
Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.
Ann Surg Oncol. 2022 Apr;29(4):2324-2331. doi: 10.1245/s10434-021-11050-6. Epub 2021 Nov 18.
10
Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.
Cancer Res Treat. 2020 Oct;52(4):1178-1187. doi: 10.4143/crt.2020.313. Epub 2020 Jun 11.
Zotero 插件